{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-25-000055","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.109519+00:00","generated_at":"2026-05-16T23:26:22.036066+00:00","sec_items":["1.01","2.02","2.03","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Altimmune Q3 net loss $19M ($0.21/sh); cash $210.8M; debt facility upsized to $125M","bullets":["Cash and investments $210.8M, up 60% from Dec 2024; net loss $19.0M vs $22.8M year ago.","Hercules loan amended to $125M; drew additional $20M at close; interest-only period extended to 30 months.","Phase 2b IMPACT 48-week MASH data expected before year end; End-of-Phase-2 FDA meeting scheduled Q4 2025.","RECLAIM AUD trial enrollment completed early; topline results expected in 2026. RESTORE ALD trial initiated.","Appointed CMO (Dr. Arbet-Engels), CCO (Richardson), and CLO (Abrams) to executive team."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-25-000055","json":"https://secwatch.observer/filing/0001326190-25-000055.json","markdown":"https://secwatch.observer/filing/0001326190-25-000055.md","text":"https://secwatch.observer/filing/0001326190-25-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619025000055/0001326190-25-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619025000055/alt-20251106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:26:22.036066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a52b8fc1cdd67844b2d42ee345f478b101e90ff8","claim":"Altimmune, Inc. amended term loan of from an aggregate principal amount of $100.0 million to $125.0 million with Hercules Capital, Inc. at greater of (a) 9.70% per annum and (b) the prime rate as reported in The Wall St maturing 30 months from May 13, 2025.","evidence_excerpt":"Company and Hercules. Under the terms of the Amendment, the lenders will, among other things, increase the availability under the Term Loan from an aggregate principal amount of $100.0 million to $125.0 million. The first Term Loan tranche was drawn down at closing on May 13, 2025 in an aggregate principal amount of $15.0 million. The second Term Loan tranche was drawn","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619025000055/0001326190-25-000055-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"from an aggregate principal amount of $100.0 million to $125.0 million"},{"label":"Counterparty","value":"Hercules Capital, Inc."},{"label":"Rate","value":"greater of (a) 9.70% per annum and (b) the prime rate as reported in The Wall St"},{"label":"Maturity","value":"30 months from May 13, 2025"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}